Equinext (EQX) a limited liability company, was formed to develop, manufacture, and sell an injectable reagent for the treatment of equine ligament, tendon tissue damage (lesions), and stifle joint injury occurring in all breeds of working and competitive horses.  Equinext released Novobrace an injectable bioadhesive, as the first in a series of their equine medical devices.


Equinext is a spinoff company of Orthopeutics with offices and laboratory on the University of Kentucky’s Coldstream Research Campus in Lexington, Kentucky.


Contact:  Eric Hauck, CEO

Email:  ehauck@equinext.com
Phone:  859.371.6263

Address: 1500 Bull Lea Road, Suite 215, Lexington, KY 40511

Website:  www.novobrace.com